Comments
Loading...

ALX Oncology Holdings

ALXONASDAQ
$6.10
-0.11-1.77%
At Close: -
$5.75
-0.35-5.74%
After Hours: 4:18 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$106.00
Lowest Price Target1
$14.00
Consensus Price Target1
$32.88

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

ALX Oncology Holdings (NASDAQ:ALXO) Stock, Analyst Ratings, Price Targets, Forecasts

ALX Oncology Holdings Inc has a consensus price target of $32.88 based on the ratings of 9 analysts. The high is $106 issued by Stifel on September 30, 2021. The low is $14 issued by Stifel on March 8, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on June 10, 2024, April 10, 2024, and March 11, 2024, respectively. With an average price target of $21.67 between HC Wainwright & Co., there's an implied 276.81% upside for ALX Oncology Holdings Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Mar
1
Apr
1
May
0
0
0
0
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Stifel
Piper Sandler
Jefferies
UBS

1calculated from analyst ratings

Analyst Ratings for ALX Oncology Holdings

Buy NowGet Alert
06/10/2024Buy Now334.78%HC Wainwright & Co.
Swayampakula Ramakanth
$25 → $25ReiteratesBuy → BuyGet Alert
05/29/2024Buy NowCantor Fitzgerald
Li Watsek
Reiterates → OverweightGet Alert
04/12/2024Buy NowCantor Fitzgerald
Li Watsek
Reiterates → OverweightGet Alert
04/10/2024Buy Now247.83%HC Wainwright & Co.
Swayampakula Ramakanth
→ $20ReiteratesBuy → BuyGet Alert
03/11/2024Buy Now247.83%HC Wainwright & Co.
Swayampakula Ramakanth
$17.5 → $20MaintainsBuyGet Alert
03/08/2024Buy Now143.48%Stifel
Bradley Canino
$10 → $14DowngradeBuy → HoldGet Alert
03/08/2024Buy Now265.22%Piper Sandler
Christopher Raymond
$11 → $21MaintainsOverweightGet Alert
12/08/2023Buy Now213.04%Jefferies
Michael Yee
$8 → $18UpgradeHold → BuyGet Alert
11/14/2023Buy Now73.91%Stifel
Bradley Canino
$11 → $10MaintainsBuyGet Alert
10/11/2023Buy Now91.3%Piper Sandler
Christopher Raymond
$8 → $11MaintainsOverweightGet Alert
10/04/2023Buy Now369.57%UBS
Colin Bristow
$29 → $27MaintainsBuyGet Alert
10/04/2023Buy Now300%Cantor Fitzgerald
Li Watsek
$18 → $23MaintainsOverweightGet Alert
10/03/2023Buy Now204.35%HC Wainwright & Co.
Swayampakula Ramakanth
$16 → $17.5ReiteratesBuy → BuyGet Alert
09/12/2023Buy Now213.04%Cantor Fitzgerald
Alethia Young
→ $18ReiteratesOverweight → OverweightGet Alert
09/07/2023Buy Now213.04%Cantor Fitzgerald
Alethia Young
→ $18ReinstatesOverweight → OverweightGet Alert
08/14/2023Buy Now213.04%Cantor Fitzgerald
Alethia Young
$22 → $18MaintainsOverweightGet Alert
08/11/2023Buy Now213.04%Cantor Fitzgerald
Alethia Young
$22 → $18MaintainsOverweightGet Alert
08/11/2023Buy Now39.13%Piper Sandler
Christopher Raymond
$48 → $8MaintainsOverweightGet Alert
08/11/2023Buy Now178.26%HC Wainwright & Co.
Swayampakula Ramakanth
$30 → $16MaintainsBuyGet Alert
07/24/2023Buy Now282.61%Cantor Fitzgerald
Alethia Young
→ $22ReiteratesOverweight → OverweightGet Alert
05/12/2023Buy Now421.74%HC Wainwright & Co.
Swayampakula Ramakanth
→ $30ReiteratesBuy → BuyGet Alert
03/15/2023Buy Now404.35%UBS
Colin Bristow
$31 → $29MaintainsBuyGet Alert
03/10/2023Buy Now491.3%Credit Suisse
Tiago Fauth
$38 → $34MaintainsOutperformGet Alert
03/10/2023Buy Now421.74%HC Wainwright & Co.
Swayampakula Ramakanth
$65 → $30MaintainsBuyGet Alert
11/09/2022Buy Now1030.43%HC Wainwright & Co.
Swayampakula Ramakanth
$80 → $65MaintainsBuyGet Alert
08/09/2022Buy Now560.87%Credit Suisse
Tiago Fauth
$43 → $38MaintainsOutperformGet Alert
06/06/2022Buy Now178.26%Stifel
Bradley Canino
$35 → $16MaintainsBuyGet Alert
05/19/2022Buy Now734.78%Piper Sandler
Christopher Raymond
$70 → $48MaintainsOverweightGet Alert
03/01/2022Buy Now526.09%Stifel
Bradley Canino
$60 → $36MaintainsBuyGet Alert
12/22/2021Buy Now334.78%Jefferies
Michael Yee
$65 → $25DowngradeBuy → HoldGet Alert
09/30/2021Buy Now1743.48%StifelInitiates → BuyGet Alert

FAQ

Q

What is the target price for ALX Oncology Holdings (ALXO) stock?

A

The latest price target for ALX Oncology Holdings (NASDAQ:ALXO) was reported by HC Wainwright & Co. on June 10, 2024. The analyst firm set a price target for $25.00 expecting ALXO to rise to within 12 months (a possible 334.78% upside). 19 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ALX Oncology Holdings (ALXO)?

A

The latest analyst rating for ALX Oncology Holdings (NASDAQ:ALXO) was provided by HC Wainwright & Co., and ALX Oncology Holdings reiterated their buy rating.

Q

When was the last upgrade for ALX Oncology Holdings (ALXO)?

A

The last upgrade for ALX Oncology Holdings Inc happened on December 8, 2023 when Jefferies raised their price target to $18. Jefferies previously had a hold for ALX Oncology Holdings Inc.

Q

When was the last downgrade for ALX Oncology Holdings (ALXO)?

A

The last downgrade for ALX Oncology Holdings Inc happened on March 8, 2024 when Stifel changed their price target from $10 to $14 for ALX Oncology Holdings Inc.

Q

When is the next analyst rating going to be posted or updated for ALX Oncology Holdings (ALXO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ALX Oncology Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ALX Oncology Holdings was filed on June 10, 2024 so you should expect the next rating to be made available sometime around June 10, 2025.

Q

Is the Analyst Rating ALX Oncology Holdings (ALXO) correct?

A

While ratings are subjective and will change, the latest ALX Oncology Holdings (ALXO) rating was a reiterated with a price target of $25.00 to $25.00. The current price ALX Oncology Holdings (ALXO) is trading at is $5.75, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch